Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases

Respiratory Research

Table 1 Patient disposition for proteomic and gene expression analyses

	Asthma (protein)	Asthma (gene expression)	COPD (protein)	COPD (gene expression)
Total patients	395	326	84	78
Placebo (all)	195	163	41^b	40^b
Placebo (EOS-high)	75	60	13	11
Placebo (EOS-low)	121	103	24	25
Benralizumab (all)	200^a	163^a	43^b	38^b
Benralizumab (EOS-high)	90	69	15	16
Benralizumab (EOS-low)	110	93	22	18

EOS-high: eosinophil count ≥300 cells/μL
EOS-low: eosinophil count < 300 cells/μL
COPD chronic obstructive pulmonary disease, EOS eosinophils
^aOne patient with asthma did not have eosinophil status and could not be designated into a subgroup for proteomic or gene expression analysis
^b10 patients with COPD did not have eosinophil status and could not be designated into subgroups for proteomic analysis; eight patients could not be designated into subgroups for gene expression analysis

ISSN: 1465-993X